About MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
Clinical Trials at MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
During the past decade, MultiCare Deaconess Cancer and Blood Specialty Center - Downtown conducted 89 clinical trials. In the 10-year time frame, 89 clinical trials started and 68 clinical trials were completed, i.e. on
average, 76.4% percent of trials that started reached the finish line to date. In the past 5 years, 20 clinical trials started and 49 clinical trials were completed. i.e. 245%
of trials that started reached the finish line.
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "MultiCare Deaconess Cancer and Blood Specialty Center - Downtown" #1 sponsor was "National Cancer Institute (NCI)" with 57 trials, followed by "Alliance for Clinical Trials in Oncology" with 30 trials
sponsored, "SWOG Cancer Research Network" with 28 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 10 trials sponsored and "NSABP Foundation Inc"
with 10 trials sponsored. Other sponsors include 10 different institutions and
companies that sponsored additional 13 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "MultiCare Deaconess Cancer and Blood Specialty Center - Downtown"
#1 collaborator was "National Cancer Institute (NCI)" with 85 trials as a collaborator, "NRG Oncology" with 17 trials as a collaborator, "Canadian Cancer Trials Group" with 8 trials as a collaborator, "Genentech, Inc." with 4 trials as a collaborator and "NCIC Clinical Trials Group" with 4 trials as a collaborator. Other collaborators include 31 different institutions and companies that were
collaborators in the rest 34 trials.
Clinical Trials Conditions at MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
According to Clinical.Site data, the most researched conditions in "MultiCare Deaconess Cancer and Blood Specialty Center - Downtown" are
"Breast Cancer" (9 trials), "Recurrent Ovarian Carcinoma" (8 trials), "Recurrent Fallopian Tube Carcinoma" (7 trials), "Recurrent Primary Peritoneal Carcinoma" (7 trials) and "Recurrent Squamous Cell Lung Carcinoma" (7 trials). Many other conditions were trialed in "MultiCare Deaconess Cancer and Blood Specialty Center - Downtown" in a lesser frequency.
Clinical Trials Intervention Types at MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
Most popular intervention types in "MultiCare Deaconess Cancer and Blood Specialty Center - Downtown" are "Drug" (118 trials), "Other" (94 trials), "Biological" (55 trials), "Procedure" (36 trials) and "Radiation" (12 trials). Other intervention types were less common.
The name of intervention was led by "Laboratory Biomarker Analysis" (49 trials), "Quality-of-Life Assessment" (35 trials), "Paclitaxel" (21 trials), "Questionnaire Administration" (21 trials) and "Computed Tomography" (19 trials). Other intervention names were less common.
Clinical Trials Genders at MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
The vast majority of trials in "MultiCare Deaconess Cancer and Blood Specialty Center - Downtown" are
101 trials for "All" genders, 39 trials for "Female" genders and 6 trials for "Male" genders.
Clinical Trials Status at MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
Currently, there are NaN active trials in "MultiCare Deaconess Cancer and Blood Specialty Center - Downtown".
undefined are not yet recruiting,
23 are recruiting,
73 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 37 completed trials in MultiCare Deaconess Cancer and Blood Specialty Center - Downtown,
2 suspended trials,
and 9 terminated clinical trials to date.
Out of the total trials that were conducted in MultiCare Deaconess Cancer and Blood Specialty Center - Downtown, 5 "Phase 1"
clinical trials were conducted, 63 "Phase 2" clinical
trials and 84 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 2 trials that are defined as “Not Applicable".